Search

Your search keyword '"Jasinska, Elzbieta"' showing total 35 results

Search Constraints

Start Over You searched for: Author "Jasinska, Elzbieta" Remove constraint Author: "Jasinska, Elzbieta"
35 results on '"Jasinska, Elzbieta"'

Search Results

4. Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

5. Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

18. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study

19. Prediction of Chronic Kidney Disease - A Machine Learning Perspective

21. Improved Gastrointestinal Tolerability Profile with Diroximel Fumarate Compared to Dimethyl Fumarate in Relapsing MS Patients (994)

22. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.

24. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

30. ESTIMATION LINEAR MODEL USING BLOCK GENERALIZED INVERSE OF A MATRIX.

31. (DXT51) High Rates of Adherence to Oral Diroximel Fumarate and Dimethyl Fumarate Are Observed and Sustained in Relapsing Multiple Sclerosis Patients.

33. Ofatumumab versus Teriflunomide in Multiple Sclerosis

34. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

35. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.

Catalog

Books, media, physical & digital resources